hit counter
Aridis Pharmaceuticals, Inc. (ARDS) Stock News Sentiment & Price - Sentifly
ARDS - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Aridis Pharmaceuticals, Inc. (ARDS)

USA
Biotechnology
NASDAQ
ARDS Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
ARDS Latest news
Zacks Investment Research
Negative
ARIDIS PHARMACT (ARDS) Reports Q2 Loss, Misses Revenue Estimates
2021-08-12 11:40

ARIDIS PHARMACT (ARDS) delivered earnings and revenue surprises of 3.51% and -91.75%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

PRNewsWire
Neutral
Aridis Pharmaceuticals Announces Second Quarter 2021 Results
2021-08-12 09:00

LOS GATOS, Calif., Aug. 12, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today reported financial and corporate results for its second quarter ended June 30, 2021.

Zacks Investment Research
Negative
Analysts Estimate ARIDIS PHARMACT (ARDS) to Report a Decline in Earnings: What to Look Out for
2021-08-03 16:47

ARIDIS PHARMACT (ARDS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRNewsWire
Neutral
Aridis Pharmaceuticals Announces $25 Million Registered Direct Offering Priced at a Premium to Market
2021-08-02 08:00

LOS GATOS, Calif., Aug. 2, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and sale of 4,947,556 shares of the Company's common stock (or common stock equivalents) and warrants to purchase up to an aggregate of 2,473,778 shares of the Company's common stock, at an effective purchase price of $5.053 per share of common stock (or common stock equivalent) and associated warrant, in a registered direct offering priced at-the-market under Nasdaq rules.

PRNewsWire
Neutral
Aridis Pharmaceuticals' COVID mAb Ranks Among the Top 5 Most Potent COVID-19 mAbs Evaluated by the Coronavirus Immunotherapeutics Consortium (CoVIC)
2021-07-26 08:30

LOS GATOS, Calif., July 26, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, announced today that animal efficacy data reported by the Coronavirus Immunotherapeutics Consortium (CoVIC) showed that the Company's COVID-19 monoclonal antibody (mAb) AR-711, one of two mAbs in the AR-712 cocktail, ranks among the top 5 most potent mAbs that the CoVIC consortium have studied to date.

Zacks Investment Research
Positive
Aridis' (ARDS) COVID Antibody Combo Neutralizes Delta Variant
2021-07-13 13:24

Aridis Pharmaceuticals' (ARDS) inhaled COVID-19 dual antibody cocktail treatment, AR-712, binds and neutralizes the Delta variant of the virus. Stock rises in after-hours trading.

Benzinga
Positive
Aridis Pharma's COVID-19 Antibody Neutralizes Delta Variant In Animal Model
2021-07-13 06:41

Aridis Pharmaceuticals Inc (NASDAQ: ARDS) has announced that its COVID-19 mAb cocktail AR-712 binds and neutralizes the Delta variant of COVID-19 at a highly effective level (~20ng/mL).  Binding analyses project that AR-712 will be effective against all variants on the U.S. CDC's variants of interest and concern lists.

PRNewsWire
Neutral
Aridis Pharmaceuticals COVID mAb AR-712 Neutralizes SARS-CoV-2 Delta Variant
2021-07-12 16:05

LOS GATOS, Calif., July 12, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, announced today that its COVID-19 mAb cocktail AR-712 binds and neutralizes the Delta variant virus SARS-CoV-2 at a highly effective level (~20ng/mL).

Zacks Investment Research
Positive
Strength Seen in ARIDIS PHARMACT (ARDS): Can Its 10% Jump Turn into More Strength?
2021-06-09 10:31

ARIDIS PHARMACT (ARDS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

PRNewsWire
Neutral
Aridis Pharmaceuticals Announces First Quarter 2021 Results
2021-05-11 16:01

LOS GATOS, Calif., May 11, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today reported financial and corporate results for the first quarter ended March 31, 2021.

Loading more news...